

tecany, jenž našel své další uplatnění této oblasti. Vzhledem k tomu, že druhá a vyšší linie metastatického karcinomu žaludku je

historicky spojena s neúspěchy, jsou výsledky studií DESTINY GASTRIC-01 a 02 zvláště povzbudivé. Lze doufat, že budoucnost terapie

Her2 pozitivního metastatického karcinomu žaludku bude kopírovat nadějný vývoj léčby takto alterovaných nádorů prsu.

LITERATURA

1. Ferlay J, Ervik M, Colombet M, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.fr/today>. Published 2022. Accessed May 19, 2024.
2. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. *Nature*. 2017;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4. PMID: 28052061; PMCID: PMC5651175.
3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014;513(7517):202-209. doi: 10.1038/nature13480. Epub 2014 Jul 23. PMID: 25079317; PMCID: PMC4170219.
4. Van Cutsem E, Bang YJ, Feng Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer*. 2015;18(3):476-484. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20. PMID: 25038874; PMCID: PMC4511072.
5. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. *Genomics*. 1989;4(3):362-366. doi: 10.1016/0888-7543(89)90343-1. PMID: 2565881.
6. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. *Ann Oncol*. 2001;12 Suppl 1:S9-13. doi: 10.1093/annonc/12.suppl_1.s9. PMID: 11521729.
7. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene*. 2007;26(45):6469-6487. doi: 10.1038/sj.onc.1210477. Epub 2007 Apr 30. PMID: 17471238; PMCID: PMC3021475.
8. Rubin I, Yarden Y. The basic biology of HER2. *Ann Oncol*. 2001;12 Suppl 1:S3-8. doi: 10.1093/annonc/12.suppl_1.s3. PMID: 11521719.
9. Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. *Cancer Discov*. 2018;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9. PMID: 29122777; PMCID: PMC5813492.
10. Nakamura Y, Kawazoe A, Lordick F, et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. *Nat Rev Clin Oncol*. 2021;18(8):473-487. doi: 10.1038/s41571-021-00492-2. Epub 2021 Mar 31. PMID: 33790428.
11. Lumish MA, Maron SB, Paroder V, et al. Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study. *J Nucl Med*. 2023;64(5):724-730. doi: 10.2967/jnuclmed.122.264470. Epub 2022 Nov 23. PMID: 36418168; PMCID: PMC10152123.
12. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*. 2010;376(9742):687-697. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum in: *Lancet*. 2010;376(9749):1302. PMID: 20728210.
13. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology*. 2008;52(7):797-805. doi: 10.1111/j.1365-2559.2008.03028.x. Epub 2008 Apr 18. PMID: 18422971.
14. Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGIC-A Randomized Phase III Trial. *J Clin Oncol*. 2016;34(5):443-451. doi: 10.1200/JCO.2015.62.6598. Epub 2015 Nov 30. PMID: 26628478.
15. Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. *Lancet Oncol*. 2018;19(10):1372-1384. doi: 10.1016/S1473-0445(18)30481-9. Epub 2018 Sep 11. PMID: 30217672.
16. Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN γ secretion. *Cancer Lett*. 2018;430:47-56. doi: 10.1016/j.canlet.2018.05.009. Epub 2018 May 8. PMID: 29746929; PMCID: PMC6004098.
17. Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature*. 2021;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15. PMID: 34912120; PMCID: PMC8959470.
18. Janjigian YY, Kawazoe A, Bai Y, Xu J, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. *Lancet*. 2023;402(10418):2197-2208. doi: 10.1016/S0140-6736(23)02033-0. Epub 2023 Oct 20. PMID: 37871604.
19. Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [online; cit. 2024-06-08]. Available from: <https://www.merck.com/news/merck-announces-phase-3-keynote-811-trial-met-dual-primary-endpoint-of-overall-survival-os-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej/>.
20. Satoh T, Xu RH, Chug HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. *J Clin Oncol*. 2014;32(19):2039-2049. doi: 10.1200/JCO.2013.53.6136. Epub 2014 May 27. PMID: 24868024.
21. Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. *Lancet Oncol*. 2017;18(5):640-653. doi: 10.1016/S1473-0445(17)30111-0. Epub 2017 Mar 23. PMID: 28343975.
22. Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG712G (T-ACT Study). *J Clin Oncol*. 2020;38(17):1919-1927. doi: 10.1200/JCO.19.03077. Epub 2020 Mar 24. PMID: 32208960.
23. Haffner I, Schierle K, Raimúndez E, et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. *J Clin Oncol*. 2021;39(13):1468-1478. doi: 10.1200/JCO.20.02761. Epub 2021 Mar 25. PMID: 33764808; PMCID: PMC8099392.
24. Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. *N Engl J Med*. 2020;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. PMID: 32469182.
25. Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. *Lancet Oncol*. 2023;24(7):744-756. doi: 10.1016/S1473-0445(23)00215-2. Epub 2023 Jun 14. PMID: 37329891.
26. Shitara K, Barlasak F, Franke F, et al. P-159 Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study. *Annals of Oncology*. 2022;33:S306-S307. <https://doi.org/10.1016/j.annonc.2022.04.249>.

Onkologie
www.onkologiecs.cz

